On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards for China and Best Practices were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on the research and analysis of the global cell manufacturing technology market in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan awarded Huakan Biotech the '2025 Global Cell Manufacturing Technology Innovation Leadership Award'. Hazmi Yusof, Senior Vice President and Malaysia Regional Head of Frost & Sullivan, and Professor Wang Yu, Chairman of the China Liver Disease Foundation, an expert consultant to the Frost & Sullivan Global Expert Advisory Group, and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented the award to Dr. Yan Xiaojun, co-founder and CTO of Huakan Biotech.
Huakan Biology
"2025 Global Cell Manufacturing Technology Innovation Leadership Award"
Hazmi Yusof, Senior Vice President and Malaysia Head of Frost & Sullivan, and Professor Wang Yu, President of the China Foundation for Hepatitis Prevention and Control, an expert advisor to the Frost & Sullivan Global Expert Advisory Group, and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented awards to Dr. Yan Xiaojun, co-founder and CTO of Huankan Biotech.
Huakan Biotechnology is an innovator on the 3D cell manufacturing track, leading a paradigm shift in CGT production with breakthroughs at the 'hundreds of billions' scale.
Huakan Biotechnology was established in 2018, originating from the transformation of Tsinghua University's research achievements. It is the world's first hard technology company to incorporate 3D porous degradable microcarriers into cell therapy process regulations. The company focuses on '3D FloTrix®Centered around the 'Cell Manufacturing Platform', it connects the entire chain of cell breeding, amplification, harvesting, and filling, achieving single-batch cell preparation at the hundred-billion level. Huakan Biotech has obtained more than 100 patents in regions such as China, the United States, the European Union, Singapore, and Japan, establishing a 'gold standard' for large-scale production of cell and gene therapy drugs in China. It has currently reached strategic cooperation with many CGT companies globally, helping multiple commercial and clinical pipelines to be approved. It has supported the approval of three new stem cell drugs for clinical trials, directly promoting the process change and market approval of China's first stem cell drug. It has taken the lead in reducing treatment costs from millions of dollars to over one hundred thousand yuan, setting a milestone for the affordability of cell therapy products.
Deeply involved in process closed-loop development, we are setting a new benchmark for “Cellular Manufacturing Factory”
As a high-quality 3D cell manufacturing expert, Huakan Biotechnology has continuously innovated to create a 3D cell manufacturing platform. It has established a process pipeline covering the entire cell production and preparation process, capable of completing large-scale, intelligent, and fully enclosed cell and derivative production and preparation.
In September 2024, Huanqian Biotechnology released a new 'hundreds of billions-level disposable cell manufacturing process and products', becoming the industry's first provider of an overall solution for [hundreds of billions-level disposable stem cell preparation]. This solution can reduce space costs by 90%, personnel costs by 80%, time costs by 80%, and reagent consumables costs by 50%, significantly improving the efficiency of scientific research and commercial transformation.
Continuously deploying in emerging overseas strategic areas
In July 2025, the overseas headquarters of Huanqian Biotechnology in Singapore and the 3D FloTrix ™ Global Experience Center were officially launched. Relying on the Southeast Asian hub to radiate into markets in the Middle East, Europe, America, Japan, and South Korea, the center helps customers build intelligent cell manufacturing platforms, break through capacity boundaries, reshape operational paradigms, and become a key driver and best partner leading the CGT industry's upgrading.
About the Frost & Sullivan Global Technology Innovation Leadership Award
The Frost & Sullivan Global Technology Innovation Leadership Award recognizes outstanding performance and achievements made by companies in technology innovation, market potential, customer service, brand, and other aspects. The Frost & Sullivan team nominates a competitive group of excellent companies to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. An independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs conducts a rigorous review of the companies nominated by the Frost & Sullivan team and decides to award the '2025 Global Cell Manufacturing Technology Innovation Leadership Award' to Huakan Biotechnology.
